- Arthrose
Intravenous infusion of autologous MSCs has shown positive results in osteoarthritis by reducing joint pain, améliorer la mobilité, and decreasing inflammation. Patients often experience improved cartilage preservation and less joint stiffness. The mechanisms include immunomodulation through secretion of anti-inflammatory cytokines, paracrine effects stimulating cartilage repair, and inhibition of catabolic enzymes that degrade cartilage matrix. MSCs home to inflamed joints via systemic circulation and promote tissue regeneration while suppressing chronic inflammation. - Polyarthrite rhumatoïde
MSC therapy can significantly alleviate symptoms of rheumatoid arthritis, such as joint swelling, douleur, et la raideur. Improvements include better joint flexibility and reduced need for immunosuppressive drugs. MSCs work by modulating the overactive immune response, decreasing pro-inflammatory cytokines (comme le TNF-α et l'IL-6), promoting regulatory T-cell activation, and directly suppressing autoreactive lymphocytes. Their systemic anti-inflammatory actions help protect joint structures from further damage. - Spondylarthrite ankylosante
Patients with ankylosing spondylitis benefit from MSC infusions through decreased spinal stiffness, réduction de la douleur, and improved flexibility. MSCs exert effects by targeting systemic inflammation, secreting anti-inflammatory factors, and modulating Th17/Treg cell balance. En plus, MSCs reduce fibrosis in spinal ligaments and help maintain vertebral mobility. Their ability to home to sites of inflammation through chemokine signals ensures targeted therapeutic action. - Arthrite psoriasique
MSC therapy offers relief for psoriatic arthritis, leading to reduced joint pain, improved skin conditions, and better mobility. Mécaniquement, MSCs downregulate Th17-driven inflammatory pathways, suppress keratinocyte hyperproliferation, and enhance skin repair via paracrine signaling. By migrating to inflamed tissues, MSCs not only protect joints but also improve skin lesions associated with psoriasis, contributing to an overall improvement in quality of life. - Lupus érythémateux systémique (LED)
In SLE, MSC infusions lead to reduced systemic inflammation, improved skin health, and decreased joint pain. MSCs achieve this by suppressing autoreactive B and T cells, increasing regulatory T cell populations, and reducing production of pathogenic autoantibodies. Through homing to inflamed organs, MSCs stabilize immune activity and promote tissue repair, particularly in kidneys, peau, and joints affected by lupus.
Vous souhaitez savoir si les programmes cliniques actuels, développements de la recherche, ou des approches thérapeutiques émergentes peuvent être pertinentes à votre situation?
Informations pédagogiques et de recherche uniquement. Les décisions médicales individuelles doivent être prises en consultation avec des professionnels de santé qualifiés..
